JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines

Haematologica

Volumn 94, Issue 3, 2009, Pages 435-437

  Porcu, Michaël ^a   Gielen, Olga ^a,b   Cools, Jan ^a,b   De Keersmaecker, Kim ^a,b,c  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Kinase; Leukemia; Oncogene

Indexed keywords

JANUS KINASE 1; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR TAL1;

CANCER CELL; GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; LETTER; LYL1 GENE; LYMPHATIC LEUKEMIA; T CELL ACUTE LYMPHOBLASTIC LEUKEMIA; TLX1 GENE;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JANUS KINASE 1; JURKAT CELLS; MUTATION; PHOSPHORYLATION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 62949102920     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.13587     Document Type: Letter

References (9)

1. De Keersmaecker K, Marynen P, Cools J. Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia. Haematologica 2005;90:1116-27.
2. Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008; 205:751-8.
3. Xiang Z, Zhao Y, Mitaksov V, Fremont DH, Kasai Y, Molitoris A, et al. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 2008;111:4809-12.
4. Jeong EG, Kim MS, Nam HK Min CK, Lee S, Chung YJ, et al. Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers. Clin Cancer Res 2008; 14:3716-21.
5. Lierman E, Lahortiga I, Van Miegroet H, Mentens N, Marynen P, Cools J. The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica 2007;92:27-34.
6. Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007;21:1658-68.
7. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007;13:1203-10.
8. De Keersmaecker K, Lahortiga I, Mentens N, Folens C, Van Neste L, Bekaert S, et al. In vitro validation of gamma-secretase inhibitors alone or in combination with other anticancer drugs for the treatment of T-cell acute lymphoblastic leukemia. Haematologica 2008;93:533-42.
9. Fröhling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, et al. identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 2007;12:501-13.